TY - T1的抗癫痫药物使用模式在儿童和成人人口医疗补助(P06.110) JF -神经学乔-神经病学SP - P06.110 LP - P06.110六世- 78 - 1补充AU - Zhixiao王盟-乔伊斯·克首页莱默盟宣李盟-朗达Copher盟——安妮特权力Y1 - 2012/04/26 UR - //www.ez-admanager.com/content/78/1_Supplement/P06.110.abstract N2 -目的:评估医疗补助癫痫患者治疗模式。背景有限研究关于癫痫治疗模式的医疗补助的人口,尤其是儿科患者。设计/方法:进行回顾性分析使用汤森路透的医疗补助计划声称来自13个州(2005 - 2009)的数据。Patients who had >=1 diagnosis of epilepsy (ICD-9-CM: 345.xx) and >1 pharmacy claims for antiepileptic drugs (AEDs) with continuous medical and pharmacy enrollment in the 6-month pre- and 12-month post-index (date of first AED prescription) periods were included. AED patterns in adult (>=18 years) and pediatric patients (2-17 years) were assessed separately. Changes in treatment patterns were compared by year of AED initiation between 2005 and 2008.Results: 5707 patients met selection criteria, 46% adult and 54% pediatric. In the 2005 pediatric cohort, the most common monotherapies were oxcarbazepine (OXC, 23%), carbamazepine (CBZ, 18%), and levetiracetam (LEV, 17%) and they changed to OXC 22%, CBZ 12%, and LEV 32% by 2008. In the 2005 adult cohort, the most common monotherapies were phenytoin (PHT, 35%), LEV (11%), and CBZ (11%) and they changed to PHT 31%, LEV 25%, CBZ 8% by 2008. The most common polytherapy for children included LEV plus another AED, while PHT plus another AED was most commonly used among adults. In the 2005 pediatric cohort, 82.0% received monotherapy (70.3% one AED and 11.7% sequential monotherapy), followed by monotherapy to polytherapy switch (12.5%), and polytherapy only (5.5%). In the 2005 adult cohort, 77.9% received monotherapy (67.9% one AED and 10% sequential monotherapy), followed by monotherapy to polytherapy switch (11.7%) and polytherapy alone (10.4%). similar patterns observed over time for both groups.Conclusions: The majority of Medicaid patients received monotherapy but changes in AED selection over time were observed among both adult and pediatric patients. There were substantial differences in AED use between the pediatric and adult patients.Supported by: Eisai Inc.Disclosure: Dr. Cramer has received personal compensation for activities with Bial, Eisai Inc., Sepracor, and UCB Pharma. Dr. Wang has received personal compensation for activities with Eisai Inc. as an employee. Dr. Li has received personal compensation for activities with Eisai Inc. as a contractor. Dr. Copher has received personal compensation for activities with Eisai Inc. Dr. Powers has received personal compensation for activities with Eisai Inc. as an employee.Thursday, April 26 2012, 07:30 am-12:00 pm ER -